FUSION ANTIBODIES PLC (FAB) — Interim results presentation

Investor webinar replay

Replay transcript excerpt

Good morning, and welcome to the FUSION ANTIBODIES PLC investor presentation. Throughout this recorded presentation, investors will be in listen only mode. Questions are encouraged and could be submitted at any time by the Q and A tab situated on the right hand corner of your screen. Simply type in your questions and press send. The company may not be in a position to answer every question received during the meeting itself. However, the company can review all questions submitted today and publish responses where it's appropriate to do so. Before we begin, I'd like to submit the following poll. And I'd now like to hand you over to Adrian Kincaid, CEO. Good morning, sir. Thank you very much, Lily. Good morning. Good morning, everybody, and thank you very much for taking time out to hear what we have to say about the period. It's just ended on September 30 this year. So I need to do the the usual disclaimer, which I will take as as read. I'm sure you're all speed readers. And what we're going to talk through today is just an introduction to the company for anybody who hasn't, come across FUSION before. Some of the highlights, financial performance, which is the the meat of the presentation, where I'll hand over to my colleague, Steven, a strategic focus update, and then a quick summary, and then we'll move through to as many of the questions as we can get answered in in time. So as I've been introduced, my name is Adrian Kincaid. I'm pleased to be the CEO of FUSION ANTIBODIES. We are an organization, a contract research organization or CEO, CRO, that offers antibody services. We're really specialists in antibodies, very important class of proteins, means that we can get to know, all the ins and outs of antibodies or awful lot of the problems that they can sometimes cre...